purple-logo2020.png
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
December 14, 2023 06:50 ET | Purple Biotech Ltd.
This acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple...
Adlai Nortye logo.png
Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
October 23, 2023 08:12 ET | Adlai Nortye Ltd.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology...
INNATEvertnoir.png
L'inclusion du premier patient dans l'essai clinique de Phase 3 avec monalizumab déclenche un paiement de 50M$ d'AstraZeneca
October 23, 2020 01:00 ET | INNATE PHARMA
Ce paiement d’étape renforce la position de trésorerie d’Innate INTERLINK-1 est la première étude de Phase 3 étudiant une approche d’immunothérapie chez des patients présentant un cancer de la tête...
INNATEvertnoir.png
First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca
October 23, 2020 01:00 ET | INNATE PHARMA
Milestone payment further bolsters Innate’s cash position  INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy...
INNATEvertnoir.png
First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca
October 23, 2020 01:00 ET | INNATE PHARMA
Milestone payment further bolsters Innate’s cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
September 28, 2020 08:45 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907...